Ikarian Capital’s CRISPR Therapeutics CRSP Stock Holding History

Ikarian Capital’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-649,400	Closed	-$40.7M	–	151
2023 Q4	$40.7M	Buy	649,400 +647,361	+31,749%	+$35.8M	3.81%	5
2023 Q3	$9.26M	Sell	2,039 -197,961	-99%	-$10.2M	1.11%	26
2023 Q2	$11.2M	Buy	+200,000	New	+$11.3M	1.79%	17
2021 Q4	–	Sell	-197,300	Closed	-$22.1M	–	204
2021 Q3	$22.1M	Sell	197,300 -2,700	-1%	-$339K	1.56%	13
2021 Q2	$32.4M	Buy	200,000 +158,100	+377%	+$19.2M	2.62%	6
2021 Q1	$5.11M	Sell	41,900 -73,400	-64%	-$11.1M	0.17%	117
2020 Q4	$17.7M	Hold	115,300	–	–	0.78%	27
2020 Q3	$9.64M	Sell	115,300 -63,800	-36%	-$5.66M	0.7%	39
2020 Q2	$13.2M	Hold	179,100	–	–	1.05%	30
2020 Q1	$7.6M	Buy	179,100 +55,400	+45%	+$2.86M	0.57%	44
2019 Q4	$7.53M	Buy	+123,700	New	+$6.75M	1.22%	25

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ikarian Capital's CRSP Position: Q1 2024 in Review

Ikarian Capital sold out of CRISPR Therapeutics (CRSP) in Q1 2024, closing a stake of 70,546 shares — an estimated $4.42M sold.

Ikarian Capital first reported a position in CRSP in Q1 2021 and held it in 5 quarters. The position peaked at $19.4M in Q2 2021. 484 funds tracked by Wall St. Rank hold CRSP as of Q1 2024.

Ikarian Capital reported no remaining CRISPR Therapeutics position as of Q1 2024 after selling out during the quarter.
Ikarian Capital sold 70,546 CRISPR Therapeutics shares in Q1 2024, an estimated $4.42M.
Ikarian Capital first reported a position in CRISPR Therapeutics in Q1 2021 and held it in 5 quarters.
Ikarian Capital's CRISPR Therapeutics position peaked at $19.4M in Q2 2021.
484 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2024.

Based on Ikarian Capital's 13F filing for Q1 2024, filed 15 May 2024.